Positive symptoms
Hallucinations, delusions and disorganised thinking. “Positive” means an experience is added, not that it is beneficial. These tend to respond most clearly to antipsychotic treatment.
Schizophrenia research is changing. New drug targets, better understanding of the brain, and a clearer picture of what actually helps. Here's what the evidence says—without the breakthrough hype.
Explore the research ↓The most important change in schizophrenia science is the recognition that one pathway—and one type of symptom—cannot explain the entire illness.
Most established antipsychotics directly affect dopamine D2 receptors. They often reduce hallucinations and delusions, but may do less for motivation, pleasure, social withdrawal and cognitive difficulties. New research is probing muscarinic signalling, genetic risk, glutamate-related pathways, learning, and the brain's interacting circuits.
Sources: 2026 clinical review · Australasian guidelines · 2025 international guideline
Hallucinations, delusions and disorganised thinking. “Positive” means an experience is added, not that it is beneficial. These tend to respond most clearly to antipsychotic treatment.
Reduced motivation, enjoyment, expression, speech or social engagement. Depression, medication sedation and environmental factors can resemble negative symptoms, making assessment important.
Problems with working memory, attention, processing speed and executive function. These can persist even when psychosis is controlled.
Weight, blood glucose, lipids, cardiovascular health, sleep, smoking and movement side effects affect everyday wellbeing and long-term health.
Negative symptoms are not automatically laziness or lack of willpower. A good assessment distinguishes primary symptoms from medication effects, depression, sleep disorders and isolation. [2]
There is no universally best antipsychotic. Choice depends on previous response, side effects, other conditions, interactions, preferences and formulation. The 2026 Australian and New Zealand guidance places particular weight on cardiometabolic effects and shared decisions. [3]
| Approach | What it can do | Important limitations |
|---|---|---|
| Antipsychotic medication e.g. aripiprazole, risperidone, paliperidone, olanzapine, lurasidone | Can reduce positive symptoms and prevent relapse. | Effects on cognition and primary negative symptoms are often limited; side effects differ substantially. |
| Long-acting injectables including paliperidone and aripiprazole formulations | Offer reliable dosing and can reduce relapse or hospitalisation for some people. | Do not remove intrinsic medication side effects; availability and intervals vary by product. |
| Clozapine | Key evidence-based option when adequate trials of other antipsychotics have not worked. | Requires specialist supervision and blood monitoring; adverse effects can be serious. |
| CBT for psychosis, education and psychosocial support | Helps reduce distress, develop coping strategies and improve functioning. | Usually complements medication rather than replacing it. |
| Cognitive remediation / exercise | Target cognitive skills and everyday functioning; exercise supports physical and mental health. | Benefits vary; access and sustained participation matter. |
Sources: Australasian GRADE · INTEGRATE · BMJ review
What is different: xanomeline activates central muscarinic M1/M4 receptors rather than directly blocking D2 receptors. Trospium helps limit peripheral cholinergic effects. US trials demonstrated symptom improvement against placebo.
Potential benefit: less dopamine-blockade-associated movement and metabolic burden in short-term trials. Trade-offs: nausea, vomiting, constipation, dyspepsia, twice-daily administration and dosing relative to meals. Longer-term retention and direct comparison with standard drugs remain important questions.
Australian availability: a September 2026 Australian clinical review reported that no TGA registration application had been submitted as of March 2026. That is not confirmation of its regulatory status today; verify the current ARTG before publishing any present-tense availability claim.
FDA approval · September 2026 Australian review · November 2026 systematic review
Designed for prominent negative symptoms, a particularly difficult treatment target. After an FDA rejection in 2024, an additional confirmatory Phase 3 trial was underway in November 2026. Results were projected for the second half of 2027; success is not guaranteed. [7]
Drugs aiming for greater muscarinic receptor selectivity, including candidates such as NBI-1117568, are being studied. Early signals are not equivalent to successful Phase 3 trials, approval, or proven long-term advantage. [8]
Other directions include dopamine-serotonin modulators, glutamate-system approaches, and compounds intended specifically for cognitive or negative symptoms. Many candidates never complete development. [8]
The goal is not merely fewer psychotic symptoms. It is a workable life, with attention to fatigue, movement disorders, sexual side effects, weight, glucose, sleep and quality of life.
Track weight, waist where appropriate, blood pressure, glucose or HbA1c, and lipids with clinical guidance. Lifestyle strategies matter throughout treatment.
Recent Australasian guidance strongly recommends adjunctive metformin for antipsychotic-associated weight gain and suggests GLP-1 receptor agonists for selected cases. These require individual medical assessment.
Akathisia can look like agitation; sedation can look like poor motivation; elevated prolactin can affect sexual function. These distinctions change management.
Assess dose, duration, adherence, substance use, medical contributors, and symptom profile before concluding that a medication has failed.
Large genome-wide studies implicate many genetic regions, each often contributing a small share of risk. A 2025 cross-ancestry analysis identified 61 previously unreported loci and proposed possible drug targets. This does not yet yield a reliable diagnostic genetic test or a personalised prescription. [9]
Scientists are investigating how glutamate signalling, inhibitory circuits, synaptic development and network coordination relate to symptoms. The biology is heterogeneous, not a single chemical imbalance. [2]
Researchers hope that combined clinical, biological and cognitive measures will predict treatment response. Reliable, widely validated tools to choose one antipsychotic for an individual are not yet routine care. [2]
Newer work looks beyond hallucination and delusion ratings to social functioning, motivation, cognition, relapse, physical health and patients' own goals. [4]
The next advance may be a better match between a person and a treatment, not a single drug that works for everyone.
Targets distress, interpretations, coping and goals. It does not require arguing someone out of their experiences. Australasian guidance recommends offering CBT for psychosis. [3]
Structured practice and strategy training that can address cognitive difficulties, especially when paired with real-world rehabilitation and support. [3]
A therapist-guided approach to distressing voices, using a digital representation of a voice. A 2026 evidence synthesis found promising results, though access, replication and implementation remain challenges. [10]
Some analyses suggest benefits of particular stimulation protocols for voices; another 2026 review found no consistent overall advantage over sham in treatment-resistant illness. It is not a universal proven solution. [11] [12]
These are directions to watch, not predicted cures. Dates for future results are estimates and may change.
| Frontier | Why researchers care | What remains unproven |
|---|---|---|
| Muscarinic-targeted medicines | A non-D2 route to improving psychosis, with potentially different side-effect profiles. | Head-to-head effectiveness, long-term outcomes, wider availability. |
| Negative-symptom medication | Could address low motivation and expression, often poorly treated today. | Whether large confirmatory trials show meaningful real-world benefit. |
| Cognitive treatments | Memory and executive function are central to work and independence. | A reproducible drug effect on cognition and daily functioning. |
| Biomarkers and patient subtypes | Could reduce trial-and-error prescribing. | Validated, affordable tools that improve decisions beyond standard clinical assessment. |
| Digital therapies and brain stimulation | May help targeted symptoms such as distressing voices. | Which protocols work for whom, durability, accessibility and independent replication. |
A glycine transporter-1 inhibitor intended to improve cognition. Three major CONNEX Phase 3 trials did not demonstrate the hoped-for benefit, a significant setback for cognitive drug development. [13]
Its efficacy against placebo is real. A November 2026 systematic review found no direct randomised head-to-head trials establishing overall superiority to established antipsychotics. [6]
For an Australian reader, research results do not automatically translate to a locally approved, affordable or accessible treatment. Confirm whether a medicine is included on the Australian Register of Therapeutic Goods and, separately, the Pharmaceutical Benefits Scheme.
The 2026 Australia–New Zealand guideline is a particularly useful guide to current care. It emphasises appropriate antipsychotic selection, offering long-acting formulations, prompt clozapine for treatment resistance, CBT for psychosis, cognitive remediation, exercise and early metabolic risk management. [3]
Psychosis, motivation, cognition, anxiety, sleep and adverse effects may need different strategies.
What would count as worthwhile improvement, and when should treatment be re-evaluated?
Ask about metabolic blood tests, movement symptoms, sexual function and daytime fatigue.
Psychosis-focused therapy, cognitive remediation, peer support, psychosocial rehabilitation and physical activity programmes may improve day-to-day life.
For urgent mental health emergencies in Australia, call 000. For non-emergency support, discuss your situation with your GP, psychiatrist or local mental health service.
Sources favour regulators, peer-reviewed research and professional guidelines. Industry statements are identified as such. This page was researched on 17 November 2026. It is a dated snapshot, not a continuously updated medical resource.